Aa
Arrowhead Research Gets Patent
Looks like ARC-520 should be coming around on schedule for phase I testing next year:
http://www.arrowheadresearch.com/press-releases/arrowhead-research-receives-notice-patent-allowance-new-formulation-dpc-sirna
http://www.arrowheadresearch.com/press-releases/arrowhead-research-receives-notice-patent-allowance-new-formulation-dpc-sirna
http://maxwellbio.com/ru/news/244
English version:
he company "Gepatera" Health Ministry received permission to conduct clinical trials
September 21, 2012
Biotech company "Gepatera" created in late 2011 for the development and commercialization of innovative products for the treatment of liver diseases, has received permission from the Ministry of Health of the Russian Federation to conduct clinical research phase Ib-IIa drug Mirkludeks B (Myrcludex B) in patients with chronic hepatitis B .
Resident Biomedical Cluster "Skolkovo" Company "Gepatera" invested by venture capital fund "Maxwell Biotech", created with the participation capital of "RVC", is engaged in the development of drugs for the treatment of chronic hepatitis B and D Myrcludex B together with the German biotechnology company MYR GmbH, a portfolio by one of Europe's largest venture capital High-Tech Gründerfonds.
The prevalence of hepatitis B is very high: about 2 billion people worldwide are carriers of the virus, of which about 350 million are chronically ill. About 5% of patients with chronic hepatitis B to detect the presence of hepatitis D. This co-infection leads to more severe course and rapid progression of liver disease. At the moment, the majority of patients with hepatitis D capabilities of a specific treatment is limited or absent.
Myrcludex B, the idea of which belonged to the 2nd largest European research institutes (National Institute of Health and Medical Research INSERM, France, and the University of Heidelberg, Germany), a peptide and to block the penetration of hepatitis B and D into normal hepatocytes (liver cells) , thus creating a reserve for liver tissue repair and prevent progression of the disease and the development of complications such as cirrhosis and hepatocellular carcinoma. This mechanism of action can hope for a cure of the disease after a limited course of therapy, which distinguishes the product from currently registered antiviral nucleotide analogs / nucleoside therapy which in most cases should be carried out for life.
Permitted MOH "Open randomized clinical trial of the drug daily Mirkludeks B (Myrcludex B) compared with entecavir in patients with HBeAg-negative chronic hepatitis B, Phase Ib-IIa» Company "Gepatera" plans to spend in specialized clinical centers in Moscow, St. Petersburg, Chelyabinsk and Samara.
Paul O. Bogomolov , Chief of Hepatology BWW MONICA named after MF Vladimir, head of the Moscow regional center of hepatology, hepatology chief of Ministry of Health of Moscow region: "Despite mass vaccination, an estimated 1.1 million people in this country each year require treatment of hepatitis B and D. Unfortunately, the current standard of care is not given the opportunity to fully address this serious medical and social problem. Based on the positive results obtained in the previous stages of the drug development Myrcludex B, we have every reason to hope that a clinical study based on a number of Russian centers will be successful. "
Alexander Alexandrov , Medical Director - CEO MYR GmbH: "This clinical trial will allow us for the first time to obtain data on the tolerability and potential therapeutic effect Myrcludex B in patients with viral hepatitis B in need of treatment. This is an important step in the development of the drug was made possible through the fruitful cooperation with the company Gepatera and Maxwell Biotech Venture Fund is an example of successful cooperation between Russian and European real estate team. "
Ian V. Ryazantsev , Director of Investment JSC "RVC": "We are always pleased when portfolio companies are created with RVC, are key milestones in its development. Despite the fact that the company "Gepatera" was established long ago, such progress means properly structured strategy for the management of business processes in the company and the high competence of its management. Together with a team of fund "Maxwell Biotech" We look forward to the positive results of studies of the drug Mirkludeks B, which will significantly advance the search for solutions to such important issues as chronic hepatitis. "
About MYR, GmbH
MYR GmbH - a German biotechnology company founded in 2010 and has exclusive worldwide rights to the drug Myrcludex. The company successfully completed pre-clinical development stage and phase 1 clinical trials of the drug Myrcludex B. Currently, the company is responsible for coordinating the work of partners and contractors involved in the development Myrcludex, and collaborates with "Gepatera" in the conduct of clinical trials.
About "Gepatera"
LLC "Gepatera" - a private biotechnology company founded in 2011. The company is a biotechnology holding "Maxwell Biotech Group" and is a resident of the Biomedical cluster innovation center "Skolkovo". The main activity of the company - the development and excretion of the Russian market of innovative products for the treatment of liver diseases. The development of the first drug company Myrcludex B is in close cooperation with the German biotechnology company MYR, GmbH, a portfolio company of one of Europe's largest venture capital High-Tech Gründerfonds.
On the "Maxwell Biotech Group"
Ltd. "Maxwell Biotech Group" - a group of developers and service companies specializing in the development of innovative biotech projects. The company attracts funding and engaged in development and market introduction of innovative products and technologies, and actively participates in building an effective infrastructure for the development of innovative companies Our experience in international management team and experts and best management practices. To date, the assets of nine biotechnology projects: the company "OncoMax", "Photonics", "Metamax", "Infekteks", "NeyroMaks", "KardioNova", "Gepatera", "Osteros Biomedica" and "Eleventa." Seven companies of the group are among the residents of the Biomedical cluster innovation center "Skolkovo", 5 of them are members of the Technology Platform "Medicine of the Future."
English version:
he company "Gepatera" Health Ministry received permission to conduct clinical trials
September 21, 2012
Biotech company "Gepatera" created in late 2011 for the development and commercialization of innovative products for the treatment of liver diseases, has received permission from the Ministry of Health of the Russian Federation to conduct clinical research phase Ib-IIa drug Mirkludeks B (Myrcludex B) in patients with chronic hepatitis B .
Resident Biomedical Cluster "Skolkovo" Company "Gepatera" invested by venture capital fund "Maxwell Biotech", created with the participation capital of "RVC", is engaged in the development of drugs for the treatment of chronic hepatitis B and D Myrcludex B together with the German biotechnology company MYR GmbH, a portfolio by one of Europe's largest venture capital High-Tech Gründerfonds.
The prevalence of hepatitis B is very high: about 2 billion people worldwide are carriers of the virus, of which about 350 million are chronically ill. About 5% of patients with chronic hepatitis B to detect the presence of hepatitis D. This co-infection leads to more severe course and rapid progression of liver disease. At the moment, the majority of patients with hepatitis D capabilities of a specific treatment is limited or absent.
Myrcludex B, the idea of which belonged to the 2nd largest European research institutes (National Institute of Health and Medical Research INSERM, France, and the University of Heidelberg, Germany), a peptide and to block the penetration of hepatitis B and D into normal hepatocytes (liver cells) , thus creating a reserve for liver tissue repair and prevent progression of the disease and the development of complications such as cirrhosis and hepatocellular carcinoma. This mechanism of action can hope for a cure of the disease after a limited course of therapy, which distinguishes the product from currently registered antiviral nucleotide analogs / nucleoside therapy which in most cases should be carried out for life.
Permitted MOH "Open randomized clinical trial of the drug daily Mirkludeks B (Myrcludex B) compared with entecavir in patients with HBeAg-negative chronic hepatitis B, Phase Ib-IIa» Company "Gepatera" plans to spend in specialized clinical centers in Moscow, St. Petersburg, Chelyabinsk and Samara.
Paul O. Bogomolov , Chief of Hepatology BWW MONICA named after MF Vladimir, head of the Moscow regional center of hepatology, hepatology chief of Ministry of Health of Moscow region: "Despite mass vaccination, an estimated 1.1 million people in this country each year require treatment of hepatitis B and D. Unfortunately, the current standard of care is not given the opportunity to fully address this serious medical and social problem. Based on the positive results obtained in the previous stages of the drug development Myrcludex B, we have every reason to hope that a clinical study based on a number of Russian centers will be successful. "
Alexander Alexandrov , Medical Director - CEO MYR GmbH: "This clinical trial will allow us for the first time to obtain data on the tolerability and potential therapeutic effect Myrcludex B in patients with viral hepatitis B in need of treatment. This is an important step in the development of the drug was made possible through the fruitful cooperation with the company Gepatera and Maxwell Biotech Venture Fund is an example of successful cooperation between Russian and European real estate team. "
Ian V. Ryazantsev , Director of Investment JSC "RVC": "We are always pleased when portfolio companies are created with RVC, are key milestones in its development. Despite the fact that the company "Gepatera" was established long ago, such progress means properly structured strategy for the management of business processes in the company and the high competence of its management. Together with a team of fund "Maxwell Biotech" We look forward to the positive results of studies of the drug Mirkludeks B, which will significantly advance the search for solutions to such important issues as chronic hepatitis. "
About MYR, GmbH
MYR GmbH - a German biotechnology company founded in 2010 and has exclusive worldwide rights to the drug Myrcludex. The company successfully completed pre-clinical development stage and phase 1 clinical trials of the drug Myrcludex B. Currently, the company is responsible for coordinating the work of partners and contractors involved in the development Myrcludex, and collaborates with "Gepatera" in the conduct of clinical trials.
About "Gepatera"
LLC "Gepatera" - a private biotechnology company founded in 2011. The company is a biotechnology holding "Maxwell Biotech Group" and is a resident of the Biomedical cluster innovation center "Skolkovo". The main activity of the company - the development and excretion of the Russian market of innovative products for the treatment of liver diseases. The development of the first drug company Myrcludex B is in close cooperation with the German biotechnology company MYR, GmbH, a portfolio company of one of Europe's largest venture capital High-Tech Gründerfonds.
On the "Maxwell Biotech Group"
Ltd. "Maxwell Biotech Group" - a group of developers and service companies specializing in the development of innovative biotech projects. The company attracts funding and engaged in development and market introduction of innovative products and technologies, and actively participates in building an effective infrastructure for the development of innovative companies Our experience in international management team and experts and best management practices. To date, the assets of nine biotechnology projects: the company "OncoMax", "Photonics", "Metamax", "Infekteks", "NeyroMaks", "KardioNova", "Gepatera", "Osteros Biomedica" and "Eleventa." Seven companies of the group are among the residents of the Biomedical cluster innovation center "Skolkovo", 5 of them are members of the Technology Platform "Medicine of the Future."
Myrcludex is doing clinical trials? Can you provide a link? From all the posts I've read, they are looking for funding and got purchased by some other company. Or was that Replicor?
Either way, you should be a little excited that Myrcludex B, Rep9AC, GS9620, and ARC-520 are getting closer.
Either way, you should be a little excited that Myrcludex B, Rep9AC, GS9620, and ARC-520 are getting closer.
All these trials are far behind schedule of how it should really be. People are suffering and dying while these companies fulfill obligations to their investors.
Next year Myrcludex will take the spot. In Russia they took a serious approach at actually helping us. So next year most of us here in states will be going abroad to finally get help. Get a surface antigen quant done without conditions and fibroscan while we at it.
Next year Myrcludex will take the spot. In Russia they took a serious approach at actually helping us. So next year most of us here in states will be going abroad to finally get help. Get a surface antigen quant done without conditions and fibroscan while we at it.
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
